Skip to main content
Uni-Bio Science Group Limited logo

Uni-Bio Science Group Limited — Investor Relations & Filings

Ticker · 690 HKEX Manufacturing
Open in API
Filings indexed 1,066 across all filing types
Latest filing 2020-04-06 Share Issue/Capital Cha…
Country HK Hong Kong
Listing HKEX 690

About Uni-Bio Science Group Limited

http://www.uni-bioscience.com

Uni-Bio Science Group Limited is an innovative biopharmaceutical enterprise specializing in the R&D, manufacturing, and sales of biological and chemical pharmaceutical products. The company's core strategy centers on regenerative medicine, focusing on therapeutic areas such as endocrinology, dermatology, and ophthalmology. Key research pipelines address bone and muscle regeneration (including osteoporosis), skin and tissue repair (burns, chronic wounds, and medical aesthetics), and ocular regeneration (corneal damage and macular degeneration). Unique technological platforms include the ECO-KSFA® micro-protein manufacturing system for high-stability biologics and smart hydrogel technology for advanced tissue engineering and targeted delivery solutions.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and pertains to changes in issued share capital and share buybacks for Uni-Bio Science Group Limited. It includes detailed information on share repurchases, issued shares, prices, and confirmations related to compliance with listing rules on the Hong Kong Stock Exchange. The content focuses on reporting share capital changes and share repurchase activities, which aligns with announcements about share issues or capital changes. It is not a full financial report, earnings release, or management discussion, nor is it a regulatory certification or legal proceeding. Therefore, the document fits best under the category of Share Issue/Capital Change (SHA). The document length (7770 characters) and detailed data support this classification with high confidence.
2020-04-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31 March 2020, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related capital changes. The content is focused on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is a regulatory filing reporting monthly share capital movements as required by the exchange. The document length is substantial (15,000 characters), and it is not an announcement of a report but the report itself. This type of document fits best under the category of Regulatory Filings (RNS), as it is a compliance report on share capital movements and does not fit into more specific categories like Share Issue/Capital Change (SHA) because it covers a broad range of share capital movements including options and warrants, and is a standard regulatory submission to the exchange.
2020-04-06 English
Next Day Disclosure Return
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Next Day Disclosure Return' and concerns changes in issued share capital and share buybacks by Uni-Bio Science Group Limited. It includes detailed information on share repurchases, issued shares, prices, and confirmations related to compliance with listing rules. The content focuses on reporting share capital changes and repurchases, which aligns with announcements about share issues or capital changes. The document is not a full financial report, earnings release, or management discussion. It is a regulatory disclosure about share capital changes and repurchases, fitting the category of Share Issue/Capital Change (SHA). The document length (7679 characters) and detailed data support it being a substantive disclosure rather than a brief announcement or certification. Therefore, the classification is SHA with high confidence.
2020-04-03 English
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the grant of share options by Uni-Bio Science Group Limited. It details the number of options granted, exercise price, vesting periods, and conditions. The document references compliance with the Listing Rules of the Hong Kong Stock Exchange and provides no financial statements or detailed financial performance data. The document length is 3489 characters, which is relatively short and typical for an announcement rather than a full report. The content focuses on share options granted to employees and eligible persons, which is a capital-related event but specifically about share options rather than new share issuance or buybacks. According to the filing definitions, announcements about share options granted under a share option scheme fall under the category of Transaction in Own Shares (POS) or Share Issue/Capital Change (SHA). However, since this is about granting options (a form of share-based compensation) and not actual issuance or buyback of shares, the closest fitting category is Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes including share options granted. Therefore, the appropriate classification is SHA with high confidence.
2020-04-02 English
ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019
Annual Report Classification · 95% confidence The document is an announcement titled 'ANNOUNCEMENT OF FINAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2019' from Uni-Bio Science Group Limited. It contains detailed financial highlights, segment financial figures, management discussion and analysis, and business review for the full fiscal year ended December 31, 2019. The content includes audited consolidated results, revenue, EBITDA, profit/loss figures, and strategic business updates. The length is substantial (15,000 characters), and the document contains actual financial data and analysis rather than just an announcement or summary. This matches the characteristics of an Annual Report (10-K) type filing, which covers the company's full-year financial performance and activities. Although it is called an announcement, the depth and detail of financial data and management discussion indicate it is the full report or a comprehensive final results report equivalent to an annual report. Therefore, the appropriate classification is Annual Report (10-K). FY 2019
2020-03-31 English
DATE OF BOARD MEETING
Report Publication Announcement Classification · 95% confidence The document is a short announcement from Uni-Bio Science Group Limited stating the date of a board meeting to approve and publish the financial results for the year ended 31 December 2019. It does not contain the financial results themselves, nor detailed financial data or analysis. The document is only notifying the market about the upcoming board meeting and the intended approval and publication of the annual results. The length is only 1625 characters, which is quite short and consistent with an announcement rather than a full report. According to the rules, such announcements about the timing of report approval and publication are classified as Report Publication Announcements (RPA).
2020-03-16 English

Browse filings by year

26 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.